Neoadjuvant chemotherapy versus primary surgery in patients with stage III/IV endometrial cancer: A National Cancer Database study. RFS in PORTEC-3 (5-year) and tempus RWD (18-month).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results